Home Blog Page 2758

Comfee Gusto AC Launched Successfully with a Vibrant Splash in Indonesia

JAKARTA, Indonesia, Aug. 11, 2025 /PRNewswire/ — Comfee, Germany’s No.1 air conditioner brand, has officially launched its Gusto series in Indonesia. The launch was paired with a vibrant summer campaign aimed at engaging young consumers through interactive experiences and online activations.

Comfee is a lifestyle-focused brand created for the younger generation. Its core idea, “cooling smart with style,” blends modern aesthetics with smart features to provide comfort, efficiency, and freedom. The brand’s slogan, “Comfee, How I Cool Smart,” reflects this mission—delivering more than just cooling, but a smarter and more expressive lifestyle.

Comfee Lauch Gusto in Indonesia Market
Comfee Lauch Gusto in Indonesia Market

The entry into the Indonesian market marks an important step in Comfee’s Southeast Asia expansion. To celebrate, Comfee rolled out the “Live Joyfully with Comfee” campaign. Through localized activities and partnerships with popular KOLs, the campaign encouraged young Indonesians to enjoy life’s vibrant moments with Comfee products. These collaborations emphasized themes of joy, freedom, and personal comfort, quickly building momentum on social media.

Comfee Gusto Won Celebrities' Recognition around Indonesia
Comfee Gusto Won Celebrities’ Recognition around Indonesia

Comfee’s social campaign led to strong engagement across platforms. Influencers from different fields showcased how Gusto air conditioners fit into their lives—highlighting features like energy management, Active Clean+, and durability. User feedback was highly positive, with many praising the product’s convenience and sleek look. Gusto series resonates with young Indonesians and is gaining recognition in the country’s competitive AC market.

ireneswnd: https://www.tiktok.com/@ireneswnd/video/7530573727642275128

Comfee’s vision goes beyond products. It aims to shape a smarter, more personalized lifestyle for young consumers. With continued innovation and a deep focus on design and user needs, Comfee is set to redefine home comfort in Indonesia and across Southeast Asia.

Comfee Official Shops:

 

Intas & Accord signs Agreement to acquire Prothya Biosolutions

AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ — Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium. Subject to the satisfaction of customary closing conditions, including regulatory clearances, the deal is anticipated to close shortly.

This proposed acquisition marks a significant step in Intas and Accord’s long-standing ambition to establish a global presence in the PDMP market, expanding Intas’s established leadership in India into a truly international footprint.

Prothya Biosolutions, with primary operations in Amsterdam and Brussels and plasma collection centres across Hungary, employs approximately 1,200 people. The company is one of Europe’s largest plasma fractionators. Formed in 2021 through the integration of Plasma Industries Belgium, originally linked to the Belgian Red Cross, and Sanquin Plasma Products, formerly a part of the Sanquin Blood Supply Foundation, Prothya brings over 60 years of experience in plasma collection and the development of PDMPs.

Binish Chudgar, Chairman of Intas & Accord, stated:

“We are delighted to expand our plasma business through the acquisition of Prothya Biosolutions. Combined with our fractionation capabilities in India, this positions us to create a truly global plasma platform—serving patients worldwide with critical, often under-prescribed, therapies.”

Intas’s plasma division in India has been supplying hospitals with PDMPs since 2015, supported by an annual fractionation capacity of over 1 million litres and exports to multiple international markets. Additional capacity is due to come online with the expansion of Intas’s Gujarat-based facility.

Nir Epstein, CEO of Prothya, commented:

“Over the past four years, we’ve expanded into new markets, advanced critical therapies, established our own plasma collection network in Hungary, and supplied plasma derivatives to some of the world’s leading PDMP companies—all while building a stronger, more resilient organization. I want to thank our dedicated team for their unwavering commitment to our patients. I believe Accord is the right company to support Prothya and its people in the next phase of growth and global expansion.”

The global market for PDMPs—particularly IVIG (intravenous immunoglobulin)—is currently valued at $30 billion and is expected to reach $50 billion by 2035. This acquisition will give Intas access to significant additional fractionation capacity, supported by Accord’s commercial footprint spanning 85 countries.

BofA Securities is acting as the exclusive financial advisor to Accord in this transaction.

Evercore is acting as the exclusive financial advisor to Prothya in this transaction.

About Intas:

Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of formulation development, manufacturing, and marketing along with backward integration of APIs.

Intas also has strong in-house biosimilar development and marketing capabilities, with more than 15 products being marketed. Intas is committed to expanding global healthcare access by providing affordable, high-quality medications through strategic partnerships and extensive R&D investment to meet the diverse needs of healthcare systems around the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare, to operate in global markets.

Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries. Intas’s remarkable success in North America and European operations has helped us emerge as a global brand in the world’s largest pharmaceutical markets.

AGEBOX Presents iKids-Growth: Pioneering Safe and Natural Support for Children’s Height Development

RICHMOND, VA., Aug. 11, 2025 /PRNewswire/ — In the field of pediatric development, a significant advancement is taking shape. For years, parents have navigated a marketplace of nutritional aidsfrom basic multivitamins to protein powderswith little more than hope to guide them. iKids-Growth marks a meaningful step forward, moving beyond passive nutritional support and toward a more proactive, biologically-informed strategy.

Agebox iKids-Growth
Agebox iKids-Growth

AGEBOX, a trailblazer in pediatric health, is responding to the growing parental demand for safe, hormone-free height support—with iKids-Growth, the first-ever supplement designed to amplify the body’s own growth signals safely and naturally.

iKids-Growth syncs with the body’s natural growth signaling system. Genetics set the blueprint for a child’s potential height, but reaching it takes precise biological signals that convert nutrients, sleep, and physical activity into measurable growth. That’s exactly what iKids-Growth targets to support. The body’s growth system follows a natural 24-hour cycle: At night the brain releases growth hormone (GH) to jumpstart growth. In response, the liver produces growth factors that directly help bones grow throughout the day. iKids-Growth’s Day & Night formula is thoughtfully built to match this rhythm, offering around-the-clock support for healthy height development.

Formulated with carefully selected ingredients such as wolfberry, astragalus and oyster extracts, iKids-Growth relies solely on nature to support healthy growth patterns. This ability to translate these gentle ingredients into targeted biological action stems from AGEBOX’s rigorous scientific approach.

Rethinking Growth Support Through Cellular Science

This approach centers on Acesvia™, AGEBOX’s proprietary screening platform that uses human primary cells to study how natural ingredients interact with key biological systems. For iKids-Growth, that means focusing on liver and bone cells to better understand how growth happens at the cellular level.

“We don’t guess. We test,” says Dr. Simon Liu, Head of Scientific Development at AGEBOX. “Primary human cells are the gold standard for studying biological activity outside the body. They’re essentially ‘living replicas’ of cells from liver and bones. Unlike lab-grown cell lines, which can behave unnaturally over time, these cells act like they would in a real body, making our results far more reliable. They’re also incredibly hard to obtain and maintain.”

Through this process, scientists at AGEBOX have screened thousands of natural, GRAS-listed ingredients. These substances are widely recognized by experts as safe based on scientific research and long-term use in food. Only ingredients that demonstrate clear, consistent enhancement for core cellular signaling related to skeletal growth are selected for further refinement and formulation, where the most efficacious compounds are isolated and optimized into synergistic blends.

While many supplements rely on tradition, trends, or marketing appeal when choosing ingredients, every component in an AGEBOX product undergoes rigorous experimental validation. This kind of scientific rigor is more often seen in pharmaceutical development than in supplements.

Always with Parents’ Concerns in Mind

As part of AGEBOX’s unwavering commitment to credibility and safety, the company is investing in over 20 clinical trials on iKids-Growth, including three randomized controlled trials (RCTs), considered the most reliable type of study used in modern clinical research. To date, over 50,000 families have chosen iKids-Growth, with ongoing real-world tracking to further validate its outcomes.

Beyond clinical data, AGEBOX pays close attention to details parents care about. Each capsule is small and easy to swallow, with carefully calibrated doses suitable for children. iKids-Growth is made in the USA, and is manufactured under FDA’s current Good Manufacturing Practices (cGMP). To ensure safety and clean labeling, every batch is independently tested by SGS, the world’s leading third-party testing organization, for the absence of synthetic hormones, heavy metals, and pesticides. Because when it comes to kids’ health, nothing less than the highest standard will do.

“Our goal was to create something parents could genuinely trust, not just because it’s clean, but because every ingredient serves a real biological purpose,” says Ryan Lawson, AGEBOX’s Chief Brand Officer. “In an industry full of unsubstantiated claims, we’re raising the bar for integrity, efficacy, and science-backed formulation. In fact, the very first user of iKids-Growth was our founder’s daughter — a reminder that we only make products we’d confidently give to our own families.”

A Decades-Long Journey Toward Better Pediatric Health

AGEBOX began exploring the effects of natural extracts on human cellular pathways long before pediatric nutrition became a mainstream focus. Since its founding in 2009, the company has built a strong scientific foundation, including the creation of a detailed map that links hundreds of natural extracts to the cellular pathways most relevant to children’s growth and development. This mapping serves as the backbone for all their product innovations.

This deep groundwork led to the creation of iKids-Growth in 2021.  Since then, AGEBOX has continued its dedicated efforts to broaden its product line, aiming to support children’s health across development, cognition, metabolism, and beyond.

To learn more about iKids-Growth, please visit: www.shop.agebox.com

The product is also available on Amazon.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

About AGEBOX

AGEBOX Inc. is a U.S.-based biotechnology company that develops evidence-based dietary supplements to support children’s growth, cognition, and metabolic health. The company’s proprietary Acesvia™ Platform uses human cell models to identify and refine GRAS-listed materials with measurable biological effects. Its formulas, supported by clinical trials, are designed to provide safe, natural, and scientifically grounded support for pediatric needs that are not fully addressed by existing solutions.

Media Contact
Company Name: AGEBOX Inc.
Contact Person: Catalina Chan
Email: info@agebox.com
Country&City
: Richmond, VA, U.S.
Website: https://shop.agebox.com/

Caliber Enters 25th Year of Empowering Global Pharma with GxP Digital Solutions

HYDERABAD, India, Aug. 11, 2025 /PRNewswire/ — Caliber, a leading global provider of GxP-compliant digital solutions for the life sciences industry, proudly announces the start of its 25th year of operations.

Caliber steps into its 25th year, marking the milestone with the unveiling of its anniversary logo alongside the team and leadership
Caliber steps into its 25th year, marking the milestone with the unveiling of its anniversary logo alongside the team and leadership

With over two decades of expertise, Caliber has helped pharmaceutical and biotechnology companies in 17 countries enhance quality systems, streamline operations, and ensure regulatory compliance.

To mark this milestone, Caliber unveiled a new anniversary logo, officially installed at the company’s India headquarters in Hyderabad.

“The logo brings together three core elements: our Impact, Purpose, and Legacy,” said Lalitha Surabhi, AVP – Strategy and Business, Caliber Technologies. “The outer ring reflects our purpose: Quality matters because life matters. We help companies deliver life-saving drugs faster by enabling them to be digitalized, audit-ready, and efficient. The four petals represent our impact through our four portfolios — Quality, Lab, Manufacturing, and Data & Insights — blooming together like a flower. The ’25 years’ signifies our legacy, built on pioneering achievements such as the first paperless lab, the first APQR solution, CPV, and the QUARI portfolio.”

Caliber has been at the forefront of the Pharma 4.0 revolution, integrating AI, GenAI, and next-generation technologies to drive end-to-end digital transformation in life sciences. Its comprehensive suite — including CaliberLIMS, EPIQ (eQMS), CaliberBRM, CaliberAPQR, CaliberEMPro, and innovations like CaliberPulse, CaliberMetrix, and the GenAI-powered CalGenie — delivers intelligent, connected, and compliant quality systems.

These solutions go beyond automation, providing real-time insights, predictive analytics, and AI-driven document generation to help quality teams make faster, more informed decisions.

“Throughout our 25 years, we have built future-driven products that add immense value to the industry,” said Sekhar Surabhi, CEO and Founder of Caliber and Chair of ISPE India’s Pharma 4.0 Community of Practice (CoP). “Even in today’s evolving technological landscape, we stay ahead with solutions that help companies address challenging regulatory, technological, and economic environments.”

Caliber’s impact spans laboratories, shop floors, and enterprise quality systems, consistently delivering measurable improvements in compliance, productivity, and business outcomes. The company remains committed to empowering pharma manufacturers to reduce manual errors, accelerate production, and achieve audit readiness through digital transformation.

With a strong foundation, deep customer partnerships, and innovation at its core, Caliber continues to shape the future of quality, driving digital excellence worldwide — because life depends on it.

Visit: www.caliberuniversal.com

 

 

Xiao-I Corporation Celebrates Eight Consecutive Years Empowering Premium Kitchen Appliance Leader with AI-Driven Customer Experience

SHANGHAI, Aug. 11, 2025 /PRNewswire/ — Xiao-I Corporation (NASDAQ: AIXI), a global leader in artificial intelligence solutions, today announced the renewal of its strategic partnership for the eighth consecutive year with a leading Chinese manufacturer and marketer of high-end kitchen appliances. This long-term collaboration underscores the critical role of Xiao-I’s AI solutions in transforming customer service, sales, and after-sales support for the consumer goods industry.

Leveraging Xiao-I’s flagship  Dialogue Robot (iBot)  and  IKBase (Intelligent Knowledge Base)  solutions, the partnership has created a seamlessly integrated intelligent service ecosystem supporting thousands of customer service agents, e-commerce representatives, and field technicians.

 Key AI-Powered Services and Value Delivered: 

  •  Unified Omnichannel Customer Support:  Providing 24/7 intelligent customer service across phone, web, app, and social channels (via iBot) for product inquiries, troubleshooting, and post-purchase support, significantly improving first-contact resolution rates and customer satisfaction.
  •  E-commerce Sales Enablement:  Powering intelligent chatbots on e-commerce platforms and brand websites to assist online shoppers with product selection, specifications, promotions, and order tracking, driving conversion rates and enhancing the digital shopping journey.
  • Scalable Technical Support & Dispatch:  Equipping the client’s vast network of over ten thousand field service technicians with AI assistance (via iBot & IKBase). Technicians access instant troubleshooting guides, installation manuals, and parts information, enabling faster, more accurate in-home service and efficient appointment management.
  •  Operational Efficiency & Cost Savings:  Automating high volumes of routine inquiries and tasks across service, sales, and technical support, freeing human staff to handle complex issues and strategic initiatives, leading to demonstrable cost reductions and productivity gains.

“Eight years of continuous partnership with this industry leader is a powerful testament to the tangible impact of our cognitive AI solutions beyond traditional sectors,” said spokesperson of Xiao-I Corporation. “For premium consumer brands, delivering exceptional, consistent, and efficient service – from the first online inquiry to the technician’s visit – is paramount. Our integrated iBot and IKBase platform provides the intelligence backbone to unify customer engagement, empower staff, and optimize complex operational chains involving thousands of agents and technicians, ultimately driving superior brand loyalty.”

About Xiao-I Corporation

Xiao-I Corporation is a leading cognitive intelligence enterprise in China that offers a diverse range of business solutions and services in artificial intelligence, covering natural language processing, voice and image recognition, machine learning, and affective computing. Since its inception in 2001, the Company has developed an extensive portfolio of cognitive intelligence technologies that are highly suitable and have been applied to a wide variety of business cases. Xiao-I powers its cognitive intelligence products and services with its cutting-edge, proprietary AI technologies to enable and promote industrial digitization, intelligent upgrading, and transformation. For more information, please visit: www.xiaoi.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, the Company’s future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, including under the section entitled “Risk Factors” in its annual report on Form 20-F filed with the SEC on May 15, 2025, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Nexteer Unveils Its MotionIQ™ Software Suite for Intelligent Motion Control

  • Accelerates Development; Enhances Quality, Safety, Performance & Cost Efficiency
  • Leverages Nexteer’s Chassis Domain Knowledge & By-Wire Technology Portfolio

AUBURN HILLS, Mich., Aug. 11, 2025 /PRNewswire/ — Nexteer Automotive today unveiled its MotionIQ™ software suite for intelligent motion control. Engineered on proven algorithms deployed in over 115 million vehicles globally, MotionIQ streamlines by-wire chassis control, development and vehicle health-monitoring workflows into a single suite, helping OEMs get to market faster while enhancing quality and cost efficiencies. 

Driving the Future of Intelligent Motion Control
Nexteer’s new software suite comprises three product groups, MotionIQ/Control™, MotionIQ/Dev™ and MotionIQ/Health™, that seamlessly work together to deliver precise motion control, accelerated chassis development and advanced predictive maintenance. They include:

  • MotionIQ/Control™: Advanced vehicle dynamics functions including Steer-by-Brake, Hands-Off Detection, Quiet Wheel Steering, Road Surface Detection and other functions for superior driving experiences. Many of these advanced, award-winning software solutions are already deployed in vehicles on the road through Nexteer’s Electric Power Steering (EPS) and Steer-by-Wire (SbW) programs.
  • MotionIQ/Dev™: Advanced software development tools, backed by Nexteer’s systems integration and software expertise, accelerate feature development from days to minutes through automated coding and integration. By combining these advanced tools, proven systems integration expertise and flexible development approaches, Nexteer empowers OEMs to safely design their own in-house steering control algorithms and seamlessly integrate new features – all within a no-code, model-based environment. This reduces costs, shortens production lead time and minimizes error-prone manual coding.
  • MotionIQ/Health™: Leverages prognostic software and AI-powered virtual sensors to continuously monitor the electrical and mechanical functionality of steering and other chassis components as well as tires. This enhances customer satisfaction by proactively predicting issues before they occur – minimizing costly fleet downtime, enabling convenient maintenance scheduling and significantly reducing diagnostic time, errors and expenses. MotionIQ/Health™ also offers valuable insights into product quality and development, helping to reduce costs for OEMs and suppliers by using anonymized data from actual lifecycle conditions.

“In today’s hyper-competitive automotive industry, OEMs are in a global race to bring high-quality, software-defined vehicles to market faster while also reducing development costs. To achieve this, suppliers must be more than partners; we must become force multipliers,” said Robin Milavec, President, Chief Technology Officer, Chief Strategy Officer and Executive Board Director, Nexteer Automotive. “Nexteer’s MotionIQ software answers this call by unifying chassis motion control, development and health-monitoring into a single suite, helping OEMs slash development cycles, drive down costs and embed the latest by-wire technologies. With MotionIQ, Nexteer is not only delivering smarter software; we’re transforming the way chassis systems are engineered and integrated at scale.”

Virtual Simulation Reduces Cost & Development Time
Nexteer also offers comprehensive testing and validation capabilities, including platforms like Hardware-in-the-Loop (HiL) and Virtual ECUs (V-ECUs) for active system simulation. Nexteer’s level three and four V-ECU enables system-level verification early in the development cycle. This allows OEMs to begin software testing before physical hardware is available and identify issues earlier to prevent costly mistakes later in development.        

Engineering Collaboration for Accelerated Development & Integration
Partners with specialized expertise and global insights, like Nexteer, are essential in helping OEMs rapidly design, develop, test and seamlessly integrate cutting-edge software solutions into vehicles, driving both innovation and efficiency. Nexteer’s team of engineers acts as an extension of its customer’s teams, championing agile software development to ensure efficient delivery, rapid prototyping and flexible products. Nexteer’s software development process has been certified ASIL (Automotive Safety Integrity Level) D compliant with the ISO 26262 Functional Safety Standard and successfully assessed for ASPICE compliance. 

Strategic Partner to Support SDV Transition
As OEMs adopt more centralized E/E architectures to support their software-defined vehicle (SDV) platforms, they are increasingly bringing software development in-house – including functions embedded in vehicle subsystems and core to their brands. Nexteer has numerous EPS and SbW production programs in development with global OEMs to deliver decoupled steering software.

This approach empowers OEM ownership of unique steering functions and accelerates speed-to-market for their SDVs. By working together in a more collaborative way, Nexteer helps drive engineering efficiencies for its customers by maintaining common software systems across vehicle platforms, enabling easier technology integration and updates, while also providing flexibility to support brand diversification needs.   

For MotionIQ™ product or sales inquiries, you can contact a Nexteer representative at SoftwareSales@nexteer.com. To learn more, please visit Nexteer.com/Software.

About Nexteer Automotive 
Nexteer Automotive (HK 1316) is a global leading motion control technology company accelerating mobility to be safe, green and exciting. Our innovative portfolio supports by-wire chassis control, including electric and hydraulic power steering systems, steer-by-wire and rear-wheel steering systems, steering columns and intermediate shafts, driveline systems, software solutions and brake-by-wire. The company solves motion control challenges across all megatrends – including electrification, software/connectivity, ADAS/automated driving and shared mobility – for global and domestic OEMs around the world including BMW, Ford, GM, RNM, Stellantis, Toyota and VW, as well as automakers in India and China including BYD, Xiaomi, ChangAn, Li Auto, Chery, Great Wall, Geely, Xpeng and others. www.nexteer.com     

Link to Nexteer Media Center & MotionIQ Press Kit 

EVERISE STRENGTHENS LEADERSHIP TEAM WITH CHIEF REVENUE OFFICER AND CHIEF FINANCIAL OFFICER APPOINTMENTS

PLANTATION, Fla., Aug. 11, 2025 /PRNewswire/ — Everise, a global leader in transforming customer experiences, today announced two senior leadership appointments as the company continues its growth trajectory and expansion in global markets. Industry veteran Robert Jimenez joins as Chief Revenue Officer (CRO), while accomplished finance leader Steven Amaya takes on the role of Chief Financial Officer (CFO).

Robert Jimenez has been appointed Chief Revenue Officer at Everise.
Robert Jimenez has been appointed Chief Revenue Officer at Everise.

 

Steven Amaya has been appointed Chief Financial Officer at Everise.
Steven Amaya has been appointed Chief Financial Officer at Everise.

These strategic appointments come as Everise continues to expand its global footprint, scale its operations, and deepen its partnerships with some of the world’s leading healthcare brands.

With more than 25 years of leadership experience at some of the most recognized global BPO and consulting firms, Robert Jimenez most recently served as CRO of Teleperformance. He has led transformative growth strategies for the likes of Cognizant, TTEC, Genpact, Capgemini, and IBM. Known for building high-performance global sales teams and forging long-term client relationships, he has delivered a consistent track record of growth while balancing profitability and innovation. As CRO, Robert will be responsible for driving Everise’s global growth strategy and all elements of commercial operations, including sales, growth marketing, and pricing strategies.

Steven Amaya brings over 15 years of finance leadership experience in high-growth, fast-paced environments, most recently serving as CFO at Carenet Health, where he led financial strategy for engagement and care management solutions to U.S. healthcare payers and providers. Prior to that, his decade-long tenure at TaskUs saw him oversee key company milestones such as its acquisition, IPO, and international expansion. As CFO, Steven will oversee Everise’s global finance, pricing, spend management, and facilities functions.

“Robert and Steven join Everise at an exciting time in our growth journey. Both senior leaders bring exceptional expertise, proven leadership, and a shared passion for building organizations that put people first while delivering outstanding results for clients. I look forward to seeing their leadership accelerate our growth and strengthen our commitment to being a trusted partner to the world’s leading healthcare brands,” shared Sudhir Agarwal, Founder & CEO, Everise.

“I am honored to join Everise and be part of such a talented, passionate team. Everise has built a reputation for innovation, exceptional service, and a culture that truly values people. I look forward to partnering with our leaders and clients to capture the next wave of growth, expand into new markets, and continue delivering outstanding experiences in every interaction,” shared Robert Jimenez, Chief Revenue Officer, Everise.

“It is a privilege to join Everise at such an exciting phase of its growth story. Our track record of excellence, strong values, and commitment to innovation are inspiring. I am looking forward to working alongside our leaders and champs to ensure our growth is supported by financial strength, operational discipline, and smart investments that enable us to serve clients and their customers better every day,” shared Steven Amaya, Chief Financial Officer, Everise.

###

About Everise
Founded in 2016, Everise is a global leader transforming customer service for the healthcare, transport, logistics, insurance, financial services, and tech sectors. Backed by Brookfield and Warburg Pincus, the company solves problems for the millions of customers of the world’s leading brands by combining the best technology with compassionate service. With 28,000 champion agents operating across eight strategic markets globally our customer service solutions are high-performing, secure, and agile, enabling businesses to scale globally while achieving top customer satisfaction. Learn more at www.weareeverise.com.

 

Bybit Rising Fund: A Global Initiative to Transform Crypto Education From the Ground Up

DUBAI, UAE, Aug. 11, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is excited to announced the launch of the Bybit Rising Fund, a groundbreaking corporate social responsibility (CSR) initiative focused on education through  impact. Spanning 15+ geographies across four continents—from Bolivia and South Africa to the Nordic capitals—the fund represents a paradigm shift from traditional one-off charitable donations to sustainable, mutually beneficial, and education-first partnerships that serve communities long-term.

Rewriting the Standard for Crypto CSR

The Rising Fund debuts as part of Bybit’s World Series of Trading (WSOT) 2025, operating under the transformative theme “Rewrite & Reshape.” This year’s competition goes beyond trading excellence to create real-world impact by allocating a portion of the prize pool to localized education initiatives, demystifying abstract blockchain concepts and utilities for the academia, researchers, developers, creators, and students alike.

Contribution to philanthropic and educational causes has been an integral part of WSOT, the longest-running crypto trading competition of its kind and Bybit’s flagship event that excites millions of traders each year.

For the first time in WSOT’s history, Bybit will decentralize control of the CSR prize pool, giving each region—from Latin America and Southeast Asia to MENA and Europe—the opportunity to directly fund and co-create educational programs, scholarships, and hackathons with local institutions. The approach strengthens project ownership and decentralizes creative power to the builders. Together, local taskforces will shape the blockchain-enabled future best suited for their realities and real-world needs.

Reshaping Access to the Industry

The Rising Fund addresses critical barriers to entry in the blockchain and cryptocurrency space through:

  • Blockchain and crypto bootcamps designed for entry-level participants
  • Beginner-focused educational courses that make complex concepts accessible
  • Stronger scholarship-backed educational support for underserved communities
  • Collaborative hackathons that unite core crypto players and foster innovation

“The Rising Fund represents our commitment to amplifying WSOT’s legacy through real-world educational support beyond just goodwill gestures,” said Ben Zhou, co-founder and CEO at Bybit. “Through strategic partnerships, Bybit creates lasting value, positioning crypto as a force for real-world utility and social mobility.”

Restrictions and user requirements apply. For the full sets of rules and terms and conditions, users will find out more about the initiative on WSOT 2025’s official page, or learn more about the competition here.

Bybit Rising Fund: A Global Initiative to Transform Crypto Education From the Ground Up
Bybit Rising Fund: A Global Initiative to Transform Crypto Education From the Ground Up

#Bybit / #TheCryptoArk  

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube